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Abstract. Ninety-five inpatients completed a dexamethasone suppression test 
(DST) within 72 hours after admission and again after at least I week of 
medication-free hospital care. The frequency of cortisol nonsuppression in 
patients with endogenous depression (ED) was high and not significantly 
different at both tests. In patients with diagnoses other than ED, the higher rate 
of cortisol nonsuppression at the first DST was associated with a significant 
decrease in test specificity. Change in postdexamethasone cortisol levels at repeat 
testing was associated with a decrease in depressive symptomatology, but was not 
related to weight change during hospitalization. 
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Several reviews of the literature have concluded that, in certain specific situations, 
the dexamethasone suppression test (DST) can contribute to the diagnostic 
evaluation of depression (Carroll, 1982; Arana et al., 1985; APA Task Force on 
Laboratory Tests in Psychiatry, 1987). Although the controversy associated with this 
topic has many sources (Carroll, 1985) some of the discrepancies in reported 
findings have been associated with the spread of DST studies into general clinical 
settings. Most early studies examined the performance of the DST in patients on 
research units; the patients usually were drug free and had been hospitalized for l-2 
weeks before the test was performed. These restrictions tend to emphasize the 
specific effects of depressive illness on the hypothalamic-pituitary-adrenal (HPA) 
axis and to diminish the nonspecific effects of other factors that activate this 
endocrine system. These factors include “psychological stress” (Mason, 1968; 
Blumenfield et al., 1970) admission to the hospital (Mason et al., 1965; Sachar, 
1967; Swigar et al., 1979) and withdrawal from medications (Devanand et al., 1984; 
Dilsaver and Greden, 1985) or acute alcohol withdrawal (Swartz and Dunner, 1982; 
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Newsom and Murray, 1983; Ravi et al., 1984; DelPorto et al., 1985). 
Although many psychiatrists in clinical practice have ordered the DST promptly 
after the patient’s hospital admission, we cannot assume that the DST will provide 
optimal diagnostic information when used in this way. In an earlier study (Carroll et 
al., 1981), we reported no significant drop in sensitivity of the DST for melancholic 
inpatients as the drug-free period of observation was extended from l-3 days to at 
least 10 days. No comparable data on nonmelancholic patients were discussed. Thus, 
although the sensitivity of the DST was unrelated to the length of time in the 
hospital, it does not necessarily follow that the same is true for the specificity of the 
test. A retrospective examination of case records (Coccaro et al., 1984) revealed that 
depressed patients who completed a DST on day 2 of hospitalization had a higher 
frequency of cortisol nonsuppression (71%) than depressed patients who were tested 
on days 3-6 (33%). This difference did not appear to result from an association 
between the severity of depression and the day of DST completion. A similar review 
of 42 depressed patients (Roy-Byrne et al., 1984) found a nonsignificant trend 
toward more frequent cortisol nonsuppression when patients were tested on days I 
or 2 of hospitalization compared with days 4, 5, or 6. By contrast, the results 
obtained in depressed patients were highly replicable in another study when the DST 
was completed on days 8 and 15 of hospitalization (Charles et al., 1982). 
In this study, we completed a DST first within 72 hours of hospitalization and 
again in the same patients after a medication-free evaluation period. This design 
permitted the assessment of any “admission effect” on the sensitivity, specificity, and 
predictive validity of the DST, as well as the test-retest reliability during the first 3 
weeks of inpatient care. 
Methods 
Patients. This study was conducted on a 22-bed general psychiatric unit and included 95 
consecutively admitted patients with the prominent symptom of depressed mood. On this unit, 
it was standard practice to discontinue all psychotropic medications gradually during the first 
week of hospitalization and complete a drug-free diagnostic evaluation during the subsequent 
week. Patients were excluded from the study if they were less than 80% of ideal body weight, 
suffered from physical illness, were taking medications known to affect the DST (Carroll et 
al., 1981) or were unable to complete the drug-free evaluation. Diagnostic evaluation 
included a structured interview using the Schedule for Affective Disorders and Schizophrenia 
(SADS) (Endicott and Spitzer, 1978) and used all available history and clinical observations. 
The diagnosis, according to Research Diagnostic Criteria (RDC) (Spitzer et al., 1978), was 
determined at the completion of the evaluation period by a consensus of the treating 
psychiatrist and the SADS interviewer. 
We studied 58 women and 37 men whose ages were 40.6 + 15.3 years and 30.0 + 10.0 years, 
respectively (mean + SD). Sixty-two patients were diagnosed as suffering from a depressive 
disorder by RDC. Thirty-seven of these met criteria for major depressive disorder (MDD), 
definite endogenous subtype (ED). The remaining 25 met criteria for MDD, not or only 
probable endogenous subtype; episodic minor depressive disorder; or chronic and intermittent 
depressive disorder (NED). The ratio of females to males was 2:1 in both ED and NED 
groups, and the mean ages were 43.6 years (range 2 l-73) and 32.7 years ( 19-60) respectively. 
The remaining patients received diagnoses of manic disorder (MAN) (n = I I); schizoaffective 
disorder, depressed type (SA-D) ( n = IO); schizoaffective disorder, manic type (SA-M) 
(n = 7); or schizophrenia (SCH) (n = 5). 
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Procedure. All patients completed a DST on two occasions before beginning treatment. 
Patients received dexamethasone at I I:30 p.m. on day I or 2 of inpatient care (DST-I), and 
plasma cortisol was measured at 4 p.m. and I I p.m. on the following day. The test was 
repeated after 7-21 days of hospitalization (DST-II). DST-I could therefore have occurred in 
the absence of recent medication ingestion, during the discontinuation of known medications, 
or following the abrupt discontinuation of alcohol, marijuana, or undisclosed medications. 
DST-II always occurred at least 7 days after cessation of medication and after at least I week 
in the hospital. The DST followed the procedure described by Carroll et al. (198 I), using I mg 
of dexamethasone, and the result was considered nonsuppressive/abnormal if either the 4 
p.m. or I I p.m. postdexamethasone plasma cortisol value exceeded 5 pg/dl. Plasma cortisol 
was determined using a competitive protein-binding method (Wilens et al., 1984). In our 
laboratory, the typical coefficients of variation are 12.5% (interassay) and 6.5% (intra-assay) 
with low cortisol samples (mean cortisol concentration, 2.5 pg/dl), and 9.0% (interassay) and 
5.5% (intra-assay) with high cortisol samples (mean cortisol concentration, lO.O~g/dl). 
Clinical ratings of severity were obtained at the time of each DST using the Hamilton 
Rating Scale for Depression (HRSD) (Hamilton, 1960). The results of the DST were not 
released to the investigators until the diagnostic evaluation was complete. 
Data Analysis. Two sets of analyses were performed on the dependent measures derived 
from the DST results. First, we calculated the frequency of “DST nonsuppression” in each 
diagnostic group and examined changes in test performance between DST-I and DST-II. The 
significance of a change in frequency between DST-I and DST-II was assessed using the 
McNemar x2 test for dependent samples (McNemar, 1947). The 95% confidence limits (CL- 
95) for estimates of conditional probabilities (sensitivity, specificity, and predictive validity) 
were determined as described previously (Kalter et al., 1983). A Kappa statistic was calculated 
for each patient group as a measure of agreement in test result between DST-I and DST-II 
(Cohen, 1960). 
In a separate analysis, we examined the actual change in maximum postdexamethasone 
cortisol levels at DST-I and DST-II. The cortisol values were log-transformed to improve the 
normality of distribution before the use of parametric statistical tests (skewness at DST-I and 
DST-II, respectively, was 0.97 and 1.32 for raw cortisol values and -0.73 and 0.24 after log 
transformation). To explore the relationship between diagnosis and change in postdexa- 
methasone cortisol values, age, weight, and HRSD score, we used a two-way analysis of 
variance (ANOVA) with diagnosis as a grouping factor and time as the repeated measures 
dimension or a one-way ANOVA as appropriate. The associations between change in post- 
dexamethasone cortisol values and patient’s age, weight, and HRSD score were studied by 
analyses of covariance (ANCOVAs). 
Results 
Table 1 shows that the frequency of abnormal DST results in all studied patients 
significantly decreased from 55% at DST-I to 36% at DST-II @ < 0.01). Although 
the sensitivity (i.e., frequency of an abnormal DST in patients with ED) also 
appeared to decrease from 70% at DST-I to 59% at DST-II, the presence of a clear 
overlap in the CL-95 for each estimate (55%-85% and 43%-75%, respectively) 
indicates that this change is inconclusive. By comparison, the overall specificity (i.e., 
frequency of a normal DST in patients with diagnoses other than ED) increased 
from 55% at DST-I to 79% at DST-II, and there was no overlap in the CL-95 for 
each estimate (45%-65% and 7 I %-87%, respectively). 
The agreement in test results between DST-1 and DST-II also tended to be higher 
in patients with ED than in other patients. The value of Kappa for the ED patients 
was 0.53, and in the remaining patients it was 0.19. The CL-95 for the difference 
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Table 1. Frequency of dexamethasone suppression test (DST) nonsuppres- 
sion and test-retest reliability within diagnostic groups 
DST-I DST-II DST 
nonsuppressed nonsuppressed unchanged 
Endogenous depression 
(ED) n = 37 26 (70%) 22 (59%) 29 (78%) 
Nonendogenous depression 
(NED) n = 25 7 (28%) 3 (12%) 19 (76%) 
Schizoaffective-depressed 
(SA-D) n = 10 4 (40%) 4 (40%) 6 (60%) 
Schizoaffective-manic 
(SA-M) n= 7 6 (86%) 3 (43%) 4 (57%) 
Manic disorder 
(MAN) n = 11 4 (36%) 2 (18%) 7 (64%) 
Schizophrenia 
(SCH) n= 5 5 (100%) 0 (0%) 0 (0%) 
All patients n = 95 52 (55%) 34 (36%) 65 (68%) 
in these Kappa values is 0.34 +_ 0.38, which just overlaps zero. A one-sided t test gives 
a p value of 0.04. Further examination of ED patients who also met psychotic 
subtype revealed that 92% of DST results were unchanged (12/ 13) and 77% (IO/ 13) 
were abnormal at both times. Eight patients also met criteria for alcoholism during 
the index episode, and three had an abnormal result at DST-I (their concurrent 
diagnoses were ED, SA-D, and SCH). None developed a clinically evident 
withdrawal syndrome, and all suppressed cortisol normally at DST-II. 
Table 2 summarizes the mean postdexamethasone cortisol levels for each 
diagnostic group. Similar to the frequency of nonsuppression, the actual cortisol 
levels decreased in all diagnostic groups between DST-I and DST-II. In the ED 
patients, however, the mean cortisol level at DST-II remained higher than the 
criterion for nonsuppression, while the comparable value in patients with NED, 
MAN, or SCH fell below the criterion. Because of small numbers of patients in many 
Table 2. Maximum postdexamethasone cortisol levels at 









n DST-I DST-II 
37 11.2 + 8.2 
25 3.9 1 4.8 
10 5.9 + 5.9 
7 12.2 Ik 6.8 
11 6.4 + 5.8 
5 10.9 f 5.0 
35 4.5 + 5.1 
8.5 + 6.7 
2.8 + 3.0 
4.1 f 3.6 
6.1 15.5 
2.8 + 3.3 
2.3 f 1.4 
3.1 13.2 
OTHER 58 6.3 + 6.0 3.3 * 3.5 
Note. DST = dexamethasone suppression test. ED = endogenous depression. NED = nonen- 
dogenous depression. SA-D = schizoaffective disorder. depressed. SA-M = schlzoaffective 
disorder, manic. SW = schizophrenia. OTHDEPR = patients with other depressive syn- 
dromes (i.e., NED or SA-D). OTHER = all other patients (i.e., NED, SA-D. SA-M, MAN, or SW). 
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of the nondepressed diagnostic groups, statistical analyses were confined to 
comparisons between patients with ED and all other patients (OTHER = NED, 
SA-D, SA-M, MAN, and SCH) or between patients with ED and patients with other 
depressive syndromes (OTHDEPR = NED or SA-D). All of the OTHER group 
presented with depressed mood, whereas the OTHDEPR group actually had a 
depressive syndrome. Comparison of postdexamethasone cortisol levels between 
these patient groups revealed significant main effects for diagnosis (ED:OTHER, 
p < 0.0001; ED:OTHDEPR, p < 0.0001) and time (ED:OTHER, p < 0.0001; 
ED:OTHDEPR, p = 0.02) but the time X diagnosis interaction was not significant 
(ED:OTHER, p = 0.5; ED:OTHDEPR, p = 0.6). From these results, it appears that 
the postdexamethasone cortisol levels were significantly higher in the ED patients, 
that cortisol levels decreased significantly between tests across diagnoses, and that 
the magnitude of the decrease was not significantly different between the ED patients 
and either comparison group. 
Although patients in the ED group were significantly older than patients in the 
OTHER and OTHDEPR groups (p = 0.0001 and p = 0.0001, respectively), age was 
not found to be a significant covariate on the cortisol level between diagnoses 
(ED:OTHER, p = 0.5; ED:OTHDEPR,p = 0.3). 
Comparison of HRSD scores between diagnostic groups, and between DST-I and 
DST-11, revealed significant main effects for group (ED:OTHER, p < 0.0001; 
ED:OTHDEPR, p < 0.0001) and time (ED:OTHER, p = 0.0001; ED:OTHDEPR, 
p = O.OOl), but the time X diagnosis interaction was not significant (ED:OTHER, 
p = 0.5; ED:OTHDEPR, p = 0.7, respectively). There was a trend for the HRSD 
score to contribute to the between group differences in cortisol level (ED:OTHER, 
p = 0.09; ED:OTHDEPR, p = 0.07). After the HRSD effect was controlled for, 
however, the main effect for diagnosis continued to have a significant effect on the 
variance in cortisol level (ED:OTHER, p = 0.006; ED:OTHDEPR, p = 0.002). 
When all patients in the study were considered, the HRSD score was a significant 
covariate on the differences in cortisol level between tests (ED:OTHER, p = 0.03) 
and after the HRSD score was controlled for, the main effect for time was no longer 
significant (ED:OTHER, p = 0.09). If only the patients with a depressive syndrome 
were considered, the HRSD score did not significantly contribute to the within- 
subject variation in cortisol level between the two tests (ED:OTHDEPR, p = 0.03). 
These results suggest that patients with ED had significantly more severe depressive 
symptomatology and that, although there was a significant decrease in severity 
between tests, the magnitude of the decrease was not significantly different between 
the ED patients and either comparison group. Although the HRSD score may 
contribute to the cortisol level differences between diagnostic groups, other factors 
are clearly important. The effect of the decrease in HRSD score between tests on the 
cortisol levels appears to be significant when all patients are considered in contrast to 
the nonsignificant effect when only patients with depressive syndromes are 
examined. 
A similar analysis of patient weights revealed no significant main effects for group 
(ED:OTHER,p = 0.07 and ED:OTHDEPR,p=OJ) or time (ED:OTHER,p = 0.4 
and ED:OTHDEPR, p = 0. I). (See Table 3.) 
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Table 3. Age, weight, and HRSD score at DST-I and DST-II (mean f SD) 
Diagnosis Age (years) 
ED 43.6 f 15.4 
NED 32.4 + 11 .l 
SA-D 26.9 + 5.0 
SA-M 26.7 k 6.8 
MAN 42.7 + 14.5 
SCH 22.2 f 3.0 
OTHDEPR 30.9 f 10.0 






153rt36 151 + 36 
135,22 137+23 
150+30 152+30 
151 +33 151 f 33 
HRSD 
26 + 7 23 f 7 
16+ 7 12+7 
18f12 16+9 
14+ 5 9f5 
9+ 5 7f5 
17+ 5 9*5 
16+ 8 13f8 
15f 8 llf7 
Note. HRSD = Hamilton Rating Scale for Depression. DST = dexamethasone suppression test. ED = endogenous 
depression. NED = nonendogenous depression. SA-D = schizoaffective disorder, depressed. SA-M = schizoaffective 
disorder, mamc. SCH = schizophrenia. OTHDEPR = patients with other depressive syndromes (i.e., NED or SA-D). 
OTHER = all other patients (I.e., NED, SA-D, SA-M, MAN, or SCH). 
On the basis of the medication history obtained at the time of admission, patients 
were categorized as medication free or withdrawn from one of the common classes 
of psychotropic medications, ethanol, or cannabis (Table 4). Many patients were 
withdrawn from multiple medications, and therefore the sum of the percentages is 
> 100%. When patients with ED were compared to all other patients (OTHER), it 
was apparent that the more frequent change from nonsuppression to suppression in 
the OTHER group could not be clearly related to withdrawal from any specific 
group of medications. 
Table 4. Preadmission medication history 
ED OTHER NED SA-D SA-M MAN SCH 
Medication free 10 (27%) 23 (40%) 
Antidepressants 17 (46%) 9 (16%) 
Neuroleptics 11 (30%) 20 (34%) 
Antiparkinsonian 2 (5%) 6 (10%) 
Benzodiazepines 7 (19%) 4 (7%) 
Lithium 1 (3%) 5 (9%) 
Ethanol/cannabis 5 (14%) 7 (12%) 









































Total (143%) (134%) (136%) (120%) (129%) (136%) (160%) 
S to NS 2 (5%) 4 (7%) 1 (4%) 2 (20%) 0 (0%) 1 (9%) 0 (0%) 
NS to S 6 (16%) 18 (31%) 5 (20%) 2 (20%) 3 (43%) 3 (27%) 5 (100%) 
Note. S = dexamethasone suppression test (DST) suppression. NS = DST nonsuppression. ED = endogenous 
depression. OTHER = all other patients. NED = nonendogenous depression. SA-D = schrzoaffectrve disorder, 
depressed. SA-M = schizoaffective disorder, manic. SCH = schizophrenra. 
Discussion 
Our principal finding was that completion of the DST within 72 hours of admission 
produced a higher frequency of cortisol nonsuppression than occurred when the 
DST was delayed until week 2 of hospitalization after the patients had been 
medication free for 1 week. Although the frequency of abnormal results at DST-I 
was increased in most diagnoses, the difference between DST-I and DST-11 was 
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inconclusive in the 37 patients with ED. This is in agreement with our previous 
report (Carroll et al., 198 I) of no significant change in DST sensitivity for ED after 
hospitalization and withdrawal from medication. In patients with diagnoses other 
than ED, however, the increase in frequency of abnormal results of DST-I was 
associated with a significant decrease in test specificity. 
The change in frequency of cortisol nonsuppression between DST-I and DST-II 
also altered the predictive value of an abnormal DST for ED (PV+) (percentage of 
patients with an abnormal DST result having a diagnosis of ED). Administration of 
the DST to all newly admitted patients resulted in a PVS of 50% (CL-95 = 40% 
60%). When the test was administered to the same patients after at least I week free 
of medication and after at least I week in the hospital, the PV+ increased to 65% 
(CL-95 = 55%75%). Since PV+ is also dependent upon the prevalence of ED in the 
tested group (Vecchio, 1966; Baldessarini et al., 1983) further improvement can be 
achieved by increasing the expected prevalence of ED in the sample. If the second 
test had been administered to only those patients with depressive syndromes (ED, 
NED, and SA-D), the PV+ would have been 76% (CL-95 = 66%-86%); after 1 week 
in hospital and medication free, nearly 8 out of every 10 depressed patients with an 
abnormal result at DST-II met diagnostic criteria for ED. 
The results also reinforce the earlier warning about interpretation of DST results 
in newly admitted psychotic patients (Carroll et al., 1976). This caution is supported 
by the report of Herz et al. (1985), who found cortisol nonsuppression in 73% of 
patients with schizophrenia or schizoaffective disorder when the DST was completed 
on days I and 2 of hospitalization. In most of their patients, the DST result 
normalized after 1 week’s treatment with neuroleptic medication. Our own results 
suggest that normalization of the DST in psychotic but nondepressed patients (SA- 
M and SCH) will frequently occur after 1 week of inpatient care without definitive 
drug treatment. This contrasts with the results from psychotic patients who also 
manifested a depressed syndrome (SA-D, ED-psychotic subtype); these patients had 
a similar frequency of cortisol nonsuppression at both times of testing. 
In this sample, patients with MAN had a low frequency of cortisol nonsup- 
pression, which was much lower than the frequency in patients meeting criteria for 
SA-M. Although other reports have noted a high frequency of cortisol non- 
suppression in mania (Graham et al., 1982; Arana et al., 1983) data from studies that 
have used alternative diagnostic criteria (such as DSM-III or ICD-9) to categorize 
affective syndromes cannot be compared directly to studies that used the RDC 
(Davidson et al., 1984). Despite having the same “diagnoses,” groups of manic 
patients diagnosed at different centers by varying diagnostic criteria will not be 
strictly comparable. 
The factors responsible for the frequent change from cortisol nonsuppression at 
DST-I to suppression at DST-II cannot be comprehensively addressed in this study. 
Although physiological factors, such as inadequate hydration, poor food intake with 
associated ketosis, and disrupted circadian rest-activity cycles, may be suspected 
(Carroll, 1984) drug withdrawal is another possibility. Rapid withdrawal of 
medication with significant anticholinergic activity is sometimes associated with 
activation of the HPA axis (Dilsaver and Greden, 1985). Many patients were being 
168 
withdrawn from various psychotropic medications during DST-I, whereas all had 
been medication free for at least I week before DST-II. Despite the significant 
decrease in frequency of cortisol nonsuppression in patients with diagnoses other 
than ED, there does not appear to be any particular class of medications that was 
most commonly discontinued after admission in these patients. Psychotropic medi- 
cations vary greatly in their pharmacological properties, and for an appropriate 
examination of this interaction, sufficient numbers of patients with the same 
diagnoses and taking single medications should have them discontinued. 
Although the frequency of cortisol nonsuppression in the ED patients did not 
decrease significantly between tests, there was a significant decrease in the absolute 
postdexamethasone cortisol level. The magnitude of this decrease in the ED patients, 
however, did not significantly differ from that seen in other depressed patients or in 
ail other patients. This suggests that the factors associated with a decreased response 
of the HPA axis to dexamethasone at DST-I compared to DST-II (i.e., more 
nonsuppression), did not appear to affect patients with ED differentially as 
compared to patients with other diagnoses. The lack of plasma dexamethasone levels 
at DST-I and DST-II prevented us from examining the contribution of changes in 
dexamethasone pharmacokinetics to this altered HPA axis response. It is notable 
that a significant fall in the postdexamethasone cortisol levels in the ED group did 
not produce a significant change in the frequency of nonsuppression in this 
diagnostic group. Inspection of the mean values in Table 2 indicates that an 
equivalent decrease in absolute postdexamethasone cortisol levels in the ED group 
did not have the same impact on the frequency on nonsuppression because, in these 
patients, most values still remained above the 5 pg/dl criterion. 
Several studies have found a positive correlation between age and post- 
dexamethasone cortisol levels in depressed patients (Asnis et al., 1981; Lewis et al., 
1984; Stokes et al., 1984). Although our patients with ED were significantly older 
than the patients with other diagnoses, ANCOVA revealed that the between- 
diagnosis difference in the postdexamethasone cortisol levels remained significant 
after controlling for the age difference. 
Similarly, there have been reports indicating that severity of depressive 
symptomatology is positively associated with cortisol nonsuppression (Miller and 
Nelson, 1987; Meador-Woodruff et al., 1988). In this study, it was expected that 
more severe depressive features would be present in patients with ED, but even after 
the difference in severity of depression was controlled for, postdexamethasone 
cortisol levels in ED patients remained significantly higher than the levels in patients 
with other diagnoses. Our results also documented a modest but generalized decrease 
in symptomatology during the medication-free evaluation. The beneficial effect of 
the inpatient milieu, although sometimes not sustained, has been commonly 
observed in patients with a wide range of presentations. Once this decrease in HRSD 
score was controlled for, the fall in postdexamethasone cortisol levels between DST- 
1 and DST-II was no longer significant, suggesting that the improvement in 
symptomatology and the decrease in cortisol levels were closely associated. Contrary 
to earlier suggestions that weight loss might be responsible for abnormal DST results 
(Berger et al., 1983; Edelstein et al., 1983) we found no significant relationship 
between change in weight and change in postdexamethasone cortisol level in the 
hospital. 
In conclusion, our results indicate that abnormal DST results are common but 
transient among nondepressed psychotic patients during the first 3 days after 
hospital admission. Nonsuppression rates are also elevated soon after admission in 
patients with mania and NED, though to a lesser extent than in psychotic patients. 
In patients with ED, a high rate of nonsuppression persisted well beyond the first 
days of hospitalization. The practical lesson from these results is that the diagnostic 
performance of the DST will be reduced if it is performed during the first few days 
after patients enter the hospital. 
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